Method of averting opioid addiction
AssigneeRegeneron Pharmaceuticals, Inc.
InventorsCatherine STEHMAN-BREEN, John DAVIS
Life of this patent
Estimating the term…
Abstract
A method of averting opioid addiction in a patient is disclosed. The method can be applied to a patient suffering from moderate to severe low back pain (LBP). The method comprises: diagnosing the patient as suffering from low back; administering to the patient a pharmaceutical composition comprising a therapeutically effective amount of an antibody that binds specifically to nerve growth factor (NGF) or an antigen binding fragment thereof; and avoiding administration of an opioid to the patient, and thereby relieving pain, and averting opioid addiction in a patient.
Claims17
-22. (canceled)
A method of treating a patient suffering from moderate to severe low back pain (LBP), wherein the low back pain is inadequately controlled by standard analgesic therapy, the method comprising:
- administering to the patient an initial dose of a pharmaceutical composition comprising 1.0 mg to 10 mg of an antibody that binds specifically to nerve growth factor (NGF) or an antigen binding fragment thereof, wherein the antibody or antigen-binding fragment comprises three heavy chain complementarity determining regions (HCDRs) and three light chain complementarity determining regions (LCDRs) contained within a heavy chain variable region (HCVR)/light chain variable region (LCVR) amino acid sequence pair of SEQ ID NOs:
- 2/10;
- administering to the patient a plurality of secondary doses of the pharmaceutical composition comprising the NGF antagonist in an amount of 1.0 mg to 10 mg;
- and
- continuing the secondary doses to obtain an improvement in a pain-associated parameter.
The method of 33, wherein the antibody comprises an HCVR having the amino acid sequence of SEQ ID NO:2 and an LCVR having the amino acid sequence of SEQ ID NO:
- 10.
Dependencies are inferred from the claim text.